RA
BMY.RT

Ramius Advisors’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Ramius Advisors’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-18,946
Closed -$13K – 423
2020
Q4 		$13K Sell
18,946
-456,687
-96% -$973K ﹤0.01% 105
2020
Q3 		$1.07M Buy
+475,633
New +$1.36M 0.26% 45
2020
Q2 		– Sell
-989,152
Closed -$3.76M – 65
2020
Q1 		$3.76M Buy
989,152
+214,961
+28% +$708K 0.95% 27
2019
Q4 		$2.33M Buy
+774,191
New +$2.01M 1% 17

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Ramius Advisors's BMY.RT Position: Q1 2021 in Review

Ramius Advisors sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 18,946 shares — an estimated $13K sold.

Ramius Advisors first reported a position in BMY.RT in Q4 2019 and held it in 4 quarters. The position peaked at $3.76M in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Ramius Advisors reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Ramius Advisors sold 18,946 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $13K.
  • Ramius Advisors first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 4 quarters.
  • Ramius Advisors's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $3.76M in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Ramius Advisors's 13F filing for Q1 2021, filed 14 May 2021.